Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Chinese Patent Office
Fish and Richardson
Medtronic
UBS
Johnson and Johnson
Citi
Cipla
US Army

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205410

« Back to Dashboard

NDA 205410 describes HEMANGEOL, which is a drug marketed by Pierre Fabre Derma and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the HEMANGEOL profile page.

The generic ingredient in HEMANGEOL is propranolol hydrochloride. There are twenty-one drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.
Summary for 205410
Tradename:HEMANGEOL
Applicant:Pierre Fabre Derma
Ingredient:propranolol hydrochloride
Patents:1
Therapeutic Class:Antimigraine Agents
Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 205410
Mechanism of ActionAdrenergic beta-Antagonists
Suppliers and Packaging for NDA: 205410
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410 NDA Pierre Fabre Pharmaceuticals, Inc. 64370-375 64370-375-50 1 BOTTLE, GLASS in 1 CARTON (64370-375-50) > 50 mL in 1 BOTTLE, GLASS
HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410 NDA Pierre Fabre Pharmaceuticals, Inc. 64370-375 64370-375-01 1 BOTTLE, GLASS in 1 CARTON (64370-375-01) > 120 mL in 1 BOTTLE, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength4.28MG/ML
Approval Date:Mar 14, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Mar 14, 2017
Regulatory Exclusivity Use:NEW PRODUCT
Regulatory Exclusivity Expiration:Mar 14, 2021
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY
Patent:➤ SubscribePatent Expiration:Oct 16, 2028Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD TO TREAT HEMANGIOMA.

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Fish and Richardson
Harvard Business School
QuintilesIMS
Cipla
Dow
Cantor Fitzgerald
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot